Weiss Ratings reaffirmed their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) in a report released on Saturday morning,Weiss Ratings reports.
Several other brokerages also recently issued reports on FDMT. The Goldman Sachs Group decreased their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Barclays decreased their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Royal Bank of Canada cut their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Finally, BMO Capital Markets downgraded 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $29.56.
Check Out Our Latest Analysis on FDMT
4D Molecular Therapeutics Stock Performance
Shares of NASDAQ FDMT traded down $0.03 during trading on Friday, hitting $3.10. The company had a trading volume of 98,581 shares, compared to its average volume of 833,199. The stock has a 50 day simple moving average of $3.33 and a 200 day simple moving average of $5.19. 4D Molecular Therapeutics has a 12 month low of $2.24 and a 12 month high of $28.93. The firm has a market capitalization of $143.61 million, a P/E ratio of -1.09 and a beta of 2.87.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02). As a group, analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.
Hedge Funds Weigh In On 4D Molecular Therapeutics
Large investors have recently modified their holdings of the stock. Barclays PLC increased its position in shares of 4D Molecular Therapeutics by 141.0% during the 3rd quarter. Barclays PLC now owns 114,848 shares of the company's stock valued at $1,241,000 after purchasing an additional 67,202 shares during the last quarter. Rhumbline Advisers increased its position in shares of 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after purchasing an additional 3,675 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of 4D Molecular Therapeutics by 139.2% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,354 shares of the company's stock valued at $364,000 after purchasing an additional 38,031 shares during the last quarter. Proficio Capital Partners LLC increased its position in shares of 4D Molecular Therapeutics by 100.0% during the 4th quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock valued at $111,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in 4D Molecular Therapeutics by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock valued at $15,933,000 after acquiring an additional 92,791 shares during the period. Institutional investors own 99.27% of the company's stock.
About 4D Molecular Therapeutics
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
